CN100409844C - 神经氨酸苷酶抑制剂 - Google Patents

神经氨酸苷酶抑制剂 Download PDF

Info

Publication number
CN100409844C
CN100409844C CNB011247142A CN01124714A CN100409844C CN 100409844 C CN100409844 C CN 100409844C CN B011247142 A CNB011247142 A CN B011247142A CN 01124714 A CN01124714 A CN 01124714A CN 100409844 C CN100409844 C CN 100409844C
Authority
CN
China
Prior art keywords
chemical compound
group
independently
alkyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB011247142A
Other languages
English (en)
Chinese (zh)
Other versions
CN1347693A (zh
Inventor
诺伯特·毕乔夫伯格
金正恩
威勒德·雷
刘洪涛
马修·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100409844(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/476,946 external-priority patent/US5866601A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN1347693A publication Critical patent/CN1347693A/zh
Application granted granted Critical
Publication of CN100409844C publication Critical patent/CN100409844C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
CNB011247142A 1995-02-27 1996-02-26 神经氨酸苷酶抑制剂 Expired - Lifetime CN100409844C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39524595A 1995-02-27 1995-02-27
US08/395,245 1995-02-27
US08/476,946 US5866601A (en) 1995-02-27 1995-06-06 Carbocyclic compounds
US08/476,946 1995-06-06
US58056795A 1995-12-29 1995-12-29
US08/580,567 1995-12-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB961901330A Division CN1185223C (zh) 1995-02-27 1996-02-26 新颖化合物,其合成方法及治疗用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100876596A Division CN100338031C (zh) 1995-02-27 1996-02-26 新颖化合物,其合成方法及治疗用途

Publications (2)

Publication Number Publication Date
CN1347693A CN1347693A (zh) 2002-05-08
CN100409844C true CN100409844C (zh) 2008-08-13

Family

ID=27410155

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB011247142A Expired - Lifetime CN100409844C (zh) 1995-02-27 1996-02-26 神经氨酸苷酶抑制剂
CNB961901330A Expired - Lifetime CN1185223C (zh) 1995-02-27 1996-02-26 新颖化合物,其合成方法及治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB961901330A Expired - Lifetime CN1185223C (zh) 1995-02-27 1996-02-26 新颖化合物,其合成方法及治疗用途

Country Status (26)

Country Link
US (3) US5952375A (cg-RX-API-DMAC7.html)
EP (1) EP0759917B1 (cg-RX-API-DMAC7.html)
JP (3) JP3300365B2 (cg-RX-API-DMAC7.html)
KR (1) KR100447096B1 (cg-RX-API-DMAC7.html)
CN (2) CN100409844C (cg-RX-API-DMAC7.html)
AT (2) ATE191711T1 (cg-RX-API-DMAC7.html)
AU (1) AU720933B2 (cg-RX-API-DMAC7.html)
BR (2) BR9607098A (cg-RX-API-DMAC7.html)
CZ (1) CZ297945B6 (cg-RX-API-DMAC7.html)
DE (4) DE69635231T2 (cg-RX-API-DMAC7.html)
DK (1) DK0759917T3 (cg-RX-API-DMAC7.html)
ES (2) ES2118674T3 (cg-RX-API-DMAC7.html)
GR (1) GR3033914T3 (cg-RX-API-DMAC7.html)
HU (1) HU228450B1 (cg-RX-API-DMAC7.html)
LU (1) LU90991I2 (cg-RX-API-DMAC7.html)
MX (1) MX9706496A (cg-RX-API-DMAC7.html)
NL (1) NL300105I2 (cg-RX-API-DMAC7.html)
NO (1) NO318455B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ306625A (cg-RX-API-DMAC7.html)
PL (1) PL194173B1 (cg-RX-API-DMAC7.html)
PT (1) PT759917E (cg-RX-API-DMAC7.html)
RU (1) RU2181357C2 (cg-RX-API-DMAC7.html)
SG (1) SG45864A1 (cg-RX-API-DMAC7.html)
SI (1) SI9620042A (cg-RX-API-DMAC7.html)
UA (1) UA56128C2 (cg-RX-API-DMAC7.html)
WO (1) WO1996026933A1 (cg-RX-API-DMAC7.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100409844C (zh) * 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US5714509A (en) * 1995-05-03 1998-02-03 The University Of Alabama Inhibitors of bacterial sialidase and methods of making and using the same
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6518438B2 (en) 1996-08-23 2003-02-11 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
US5859284A (en) * 1996-08-23 1999-01-12 Gilead Sciences, Inc. Preparation of carbocyclic compounds
EP0920410B1 (en) * 1996-08-23 2002-03-27 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
CN1238762A (zh) * 1996-10-21 1999-12-15 吉里德科学公司 哌啶化合物
US5994377A (en) * 1996-10-21 1999-11-30 Gilead Sciences, Inc. Piperidine compounds
KR20000068986A (ko) * 1996-11-14 2000-11-25 리차드웨드레이 신규 용도 화합물 및 그 제조방법
WO1999006369A1 (en) * 1997-08-01 1999-02-11 University Of Florida Neuraminidase inhibitors
US5886213A (en) * 1997-08-22 1999-03-23 Gilead Sciences, Inc. Preparation of carbocyclic compounds
US20040053999A1 (en) * 1997-09-17 2004-03-18 Bischofberger Norbert W. Novel compounds and methods for synthesis and therapy
KR20010024123A (ko) * 1997-09-17 2001-03-26 헨슬레이 맥스 디. 6-원 고리를 갖는 화합물, 그의 제조 방법 및의약물로서의 용도
TW477783B (en) * 1997-12-12 2002-03-01 Gilead Sciences Inc Novel compounds useful as neuraminidase inhibitors and pharmaceutical compositions containing same
PT1040094E (pt) * 1997-12-17 2009-06-03 Biocryst Pharm Inc Compostos de ciclopentano e de ciclopenteno substituídos úteis como inibidores da neuraminidase
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
WO1999054299A1 (en) * 1998-04-23 1999-10-28 Abbott Laboratories Pyrrolidines as inhibitors of neuraminidases
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
DK0957078T3 (da) * 1998-05-13 2002-04-02 Hoffmann La Roche Fremgangsmåde til fremstilling af shikimisyre og derivater deraf
WO2000029385A1 (en) * 1998-11-13 2000-05-25 Gilead Sciences, Inc. 1,4,5,6-tetrahydro-pyridazine derivatives, their preparation and their use as neuraminidase inhibitors
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1059283B1 (en) 1999-06-11 2003-05-28 F. Hoffmann-La Roche Ag Process for preparing neuraminidase inhibitor ro-64-0796
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
WO2001028981A1 (en) * 1999-10-19 2001-04-26 Abbott Laboratories 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
US6593314B1 (en) 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
US6627396B1 (en) * 1999-10-28 2003-09-30 The Regents Of The University Of California Influenza sensor
JP2001131144A (ja) * 1999-11-02 2001-05-15 Sagami Chem Res Center 7−アザビシクロ[4.1.0]ヘプト−3−エン−3−カルボン酸エステル類の製造方法
US6462226B1 (en) 1999-12-03 2002-10-08 Hoffmann-La Roche Inc. Process for the preparation of 4,5-diamino shikimic acid derivatives
EP1486499A1 (en) 1999-12-27 2004-12-15 Sagami Chemical Research Center Endo-2,3-epoxy-7-oxabicylco[2.2.1]heptane-endo-5-carboxylic acid derivative
US8642051B2 (en) * 2000-03-21 2014-02-04 Suzanne Jaffe Stillman Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s)
AU2001252578A1 (en) * 2000-04-25 2001-11-07 Sankyo Company Limited Preventives for influenza
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
ES2269441T3 (es) 2000-06-27 2007-04-01 F. Hoffmann-La Roche Ag Metodo para la preparacion de una composicion.
AUPR001000A0 (en) 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
WO2002092555A1 (en) * 2001-05-11 2002-11-21 Sankyo Company, Limited Sialic acid derivatives
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
RU2220739C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Интраназальное средство
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US7122684B2 (en) 2003-03-13 2006-10-17 Roche Colorado Corporation Process for preparing 1,2-diamino compounds
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2007053792A2 (en) * 2005-11-05 2007-05-10 Amplyx Pharmaceuticals, Inc. Improving the pharmacokinetics of protease inhibitors and other drugs
ATE510813T1 (de) * 2005-11-25 2011-06-15 Hetero Drugs Ltd Verbessertes verfahren für oseltamivirphosphat
KR100819759B1 (ko) 2005-12-01 2008-04-07 (주)파인켐 아자이드 화합물의 폭발성을 제거한 공정을 이용한 1,2-다이아미노 화합물 또는 이의 부가염 제조 방법
EP2178819A2 (en) 2005-12-28 2010-04-28 F.Hoffmann-La Roche Ag Epoxide intermediate in the tamiflu synthesis
AU2007218733B2 (en) 2006-02-20 2012-11-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
AU2008208865B2 (en) 2007-01-23 2013-01-24 Therapicon Srl Antiviral compounds
US20080194801A1 (en) * 2007-02-14 2008-08-14 Swanson Basil I Robust multidentate ligands for diagnosis and anti-viral drugs for influenza and related viruses
US8435769B2 (en) * 2007-04-13 2013-05-07 Monsanto Technology Llc Use of glyphosate to produce shikimic acid in microorganisms
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
CN101883569B (zh) * 2007-08-31 2013-08-21 梁启铭 具有抗流感活性之含奥司他伟膦酸酯同系物的合成
US8344178B2 (en) 2007-10-16 2013-01-01 Monsanto Technology Llc Processes for producing and recovering shikimic acid
US20100284993A1 (en) * 2007-10-24 2010-11-11 Mutz Mitchell W Enhancing the Efficacy of Anti-Infective Therapeutics
WO2009078813A1 (en) * 2007-12-19 2009-06-25 Nanyang Technological University Method of forming oseltamivir and derivatives thereof
US8334319B2 (en) * 2008-01-04 2012-12-18 Roche Palo Alto Llc Polymorphic forms of oseltamivir phosphate
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20120058937A9 (en) 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
TWI491416B (zh) 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
CN101486664B (zh) * 2008-12-31 2013-09-04 北京大学深圳研究生院 用作流感病毒神经氨酸酶抑制剂的多取代五元环小分子化合物
BRPI1010981A2 (pt) 2009-05-15 2018-12-04 Redx Pharma Ltd "derivados de fármaco redox"
WO2011021223A2 (en) * 2009-08-19 2011-02-24 Msn Laboratories Limited Novel salts of ethyl (3r, 4s, 5r)-4,5-imino-3-(l-ethylpropoxy)-1- cvclohexene-1-carboxylate and its use
CN102597120B (zh) * 2009-11-11 2015-05-27 3M创新有限公司 聚合物组合物及其制备方法和制品
IT1396620B1 (it) 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
WO2012010276A1 (en) 2010-07-16 2012-01-26 Grindeks Derivatives of 1,4-dihydropyridine possessing antiviral efficacy
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
EP2578218A1 (en) 2011-10-06 2013-04-10 Grindeks, A Joint Stock Company Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate) and its derivatives
DE102011117128A1 (de) 2011-10-28 2013-05-02 Christian-Albrechts-Universität Zu Kiel Verbindungen zur Therapie der Influenza
RU2469020C1 (ru) * 2011-11-08 2012-12-10 Александр Васильевич Иващенко (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения
RU2489422C1 (ru) * 2012-05-12 2013-08-10 Александр Васильевич Иващенко Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси)циклогексен-1-карбоновые кислоты, их эфиры и способ применения
RU2521593C1 (ru) * 2013-02-27 2014-06-27 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Моно и дифторзамещенные этил (3r,4r,5s)-5-азидо-4-ацетиламино-3-(1-этилпропокси)-циклогексен-1-карбоксилаты, способ получения и применения
JP6453050B2 (ja) * 2013-11-15 2019-01-16 国立大学法人富山大学 2−デオキシ−2,3−ジデヒドロシアル酸誘導体およびその製造法
CN103819357B (zh) * 2014-01-28 2016-03-16 浙江大学 (-)-有效霉醇叠氮四乙酸酯的制备方法
CA2939491A1 (en) * 2014-02-14 2015-08-20 Toa Eiyo Ltd. Cyclic hydrocarbon compound
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
US9392814B2 (en) 2014-06-06 2016-07-19 Nicholas J. Singer Delivery system for drinks
GB2532178A (en) * 2014-06-09 2016-05-18 Redx Pharma Plc Antiviral compounds
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
USD773313S1 (en) 2015-06-23 2016-12-06 Nicholas J. Singer Package
US10676428B2 (en) 2015-12-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Antiviral agents for amantadine-resistant influenza A
KR102339817B1 (ko) 2016-06-30 2021-12-16 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법
US10759814B2 (en) * 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
KR20200106607A (ko) 2019-03-05 2020-09-15 주식회사 코아팜바이오 오셀타미비르 함유 의약 조성물
WO2025221915A1 (en) * 2024-04-16 2025-10-23 University Of Utah Research Foundation Synthesis of gadusol and related compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006691A1 (en) * 1990-10-19 1992-04-30 Biota Scientific Management Pty. Ltd. Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
EP0539204A1 (en) * 1991-10-23 1993-04-28 Biota Scientific Management Pty. Ltd. Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
WO1993012105A1 (en) * 1991-12-17 1993-06-24 Glaxo Group Limited Preparation of n-acetyl neuraminic derivatives
US5360817A (en) * 1990-04-24 1994-11-01 Biota Scientific Management Pty Ltd Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5206400A (en) * 1986-07-07 1993-04-27 Ohio State University Diastereomeric mono- and di-substituted diamino cyclohexane compounds and the method of preparation thereof
AU2947889A (en) * 1988-01-12 1989-08-11 Board Of Regents, The University Of Texas System Histamine release inhibitory factor and preparations therefore
US5175273A (en) * 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5270340A (en) * 1988-12-27 1993-12-14 Bayer Aktiengesellschaft Substituted 2-cyclohexen-1-yl-amine fungicidal and herbicidal agents
GB2238049A (en) * 1989-11-22 1991-05-22 Ki Nii Epidemiologii I Infekts Method for preparing inhibitor for influenza virus neuraminidase
DE4033415A1 (de) * 1990-10-20 1992-04-23 Bayer Ag Antimikrobielle mittel sowie substituierte 2-cyclohexan-1-yl-amin-derivate und deren herstellung
DE4131311A1 (de) * 1991-09-20 1993-04-01 Basf Ag Dihydropyranderivate und diese enthaltende pflanzenschutzmittel
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
US5292938A (en) * 1992-04-13 1994-03-08 Associated Universities, Inc. Synthesis of 4-substituted-trans-1, 2-diaminocyclohexyl polyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and spect and pet imaging
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
GB9220241D0 (en) * 1992-09-25 1992-11-11 Glaxo Group Ltd Process
GB9220327D0 (en) * 1992-09-25 1992-11-11 Glaxo Group Ltd Process
US5639786A (en) * 1992-12-04 1997-06-17 Biota Scientific Management, Pty., Ltd. Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of α-D-neuraninic acid
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
GB9311873D0 (en) * 1993-06-09 1993-07-28 Glaxo Group Ltd Process
GB9311892D0 (en) * 1993-06-09 1993-07-28 Glaxo Wellcome Australia Ltd Device
GB9312531D0 (en) * 1993-06-17 1993-08-04 Glaxo Group Ltd Process
GB9325841D0 (en) * 1993-12-17 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9400206D0 (en) * 1994-01-07 1994-03-02 Glaxo Group Ltd Chemical compound
AUPM354694A0 (en) * 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
GB9410817D0 (en) * 1994-05-28 1994-07-20 Glaxo Group Ltd Medicaments
AUPM725794A0 (en) * 1994-08-03 1994-08-25 Biota Scientific Management Pty Ltd Chemical compounds
US5556963A (en) * 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
GB9416365D0 (en) * 1994-08-12 1994-10-05 Glaxo Group Ltd Medicaments
US5512596A (en) * 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
EP0789695A2 (en) 1994-11-04 1997-08-20 Gilead Sciences, Inc. Thiepane compounds inhibiting and detecting hiv protease
CN100409844C (zh) * 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US5866601A (en) * 1995-02-27 1999-02-02 Gilead Sciences, Inc. Carbocyclic compounds
US5602277A (en) 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5714509A (en) * 1995-05-03 1998-02-03 The University Of Alabama Inhibitors of bacterial sialidase and methods of making and using the same
GB9525389D0 (en) 1995-12-12 1996-02-14 Biota Scient Management Ltd Chemical compounds
ATE206116T1 (de) * 1995-05-19 2001-10-15 Biota Scient Management 6-carboxamido-dihydropyran-derivate
GB9510141D0 (en) 1995-05-19 1995-07-12 Biota Scient Management Chemical compounds
GB9516276D0 (en) * 1995-08-08 1995-10-11 Biota Scient Management Chemical compounds
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
EP0920410B1 (en) 1996-08-23 2002-03-27 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
US5859284A (en) 1996-08-23 1999-01-12 Gilead Sciences, Inc. Preparation of carbocyclic compounds
AU711845B2 (en) * 1996-09-10 1999-10-21 Daikin Industries, Ltd. 4-substituted-2,7-dideoxy-7-fluoro-2,3-didehydro-sialic acid compounds
US5886213A (en) 1997-08-22 1999-03-23 Gilead Sciences, Inc. Preparation of carbocyclic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360817A (en) * 1990-04-24 1994-11-01 Biota Scientific Management Pty Ltd Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents
WO1992006691A1 (en) * 1990-10-19 1992-04-30 Biota Scientific Management Pty. Ltd. Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
EP0539204A1 (en) * 1991-10-23 1993-04-28 Biota Scientific Management Pty. Ltd. Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
WO1993012105A1 (en) * 1991-12-17 1993-06-24 Glaxo Group Limited Preparation of n-acetyl neuraminic derivatives

Also Published As

Publication number Publication date
CZ269097A3 (en) 1997-11-12
JP3300365B2 (ja) 2002-07-08
JP2006036770A (ja) 2006-02-09
BR9607098B8 (pt) 2014-11-18
HK1026893A1 (en) 2000-12-29
RU2181357C2 (ru) 2002-04-20
KR100447096B1 (ko) 2005-10-11
MX9706496A (es) 1997-11-29
ES2249863T3 (es) 2006-04-01
PL194173B1 (pl) 2007-05-31
CN1185223C (zh) 2005-01-19
NO318455B1 (no) 2005-03-21
HUP9800026A2 (hu) 1999-09-28
NO973908D0 (no) 1997-08-26
DE69607704D1 (de) 2000-05-18
PL322000A1 (en) 1998-01-05
DE69635231T2 (de) 2006-07-13
UA56128C2 (uk) 2003-05-15
US6225341B1 (en) 2001-05-01
DK0759917T3 (da) 2000-07-31
DE69607704T2 (de) 2000-12-28
JPH11501908A (ja) 1999-02-16
PT759917E (pt) 2000-10-31
AU5357196A (en) 1996-09-18
KR19980703600A (ko) 1998-12-05
NL300105I1 (nl) 2003-01-06
DE759917T1 (de) 1998-10-22
NL300105I2 (nl) 2003-02-03
HU228450B1 (en) 2013-03-28
ES2118674T3 (es) 2000-08-16
LU90991I2 (fr) 2003-02-11
SG45864A1 (en) 1999-04-27
ATE305453T1 (de) 2005-10-15
AU720933B2 (en) 2000-06-15
BR9607098A (pt) 1997-11-04
US5952375A (en) 1999-09-14
NO973908L (no) 1997-10-27
DE10299052I1 (de) 2003-05-22
NZ306625A (en) 2001-04-27
DE69635231D1 (de) 2006-02-09
ES2118674T1 (es) 1998-10-01
GR3033914T3 (en) 2000-11-30
CN1347693A (zh) 2002-05-08
JP2002161074A (ja) 2002-06-04
HUP9800026A3 (en) 2002-04-29
EP0759917B1 (en) 2000-04-12
SI9620042A (sl) 1998-12-31
WO1996026933A1 (en) 1996-09-06
EP0759917A1 (en) 1997-03-05
JP4234917B2 (ja) 2009-03-04
CZ297945B6 (cs) 2007-05-02
US20050176758A1 (en) 2005-08-11
CN1147813A (zh) 1997-04-16
ATE191711T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
KR100447096B1 (ko) 바이러스성또는세균성뉴라미니다제의신규한선택적저해제
US5763483A (en) Carbocyclic compounds
KR20010024123A (ko) 6-원 고리를 갖는 화합물, 그의 제조 방법 및의약물로서의 용도
WO1996026933A9 (en) Novel selective inhibitors of viral or bacterial neuraminidases
JP2008273948A (ja) ウイルスまたは細菌ノイラミニダーゼの新規な選択的インヒビター
US20040053999A1 (en) Novel compounds and methods for synthesis and therapy
JP2001502690A (ja) ピペリジン化合物
HK1120494B (en) Novel compounds and methods for synthesis and therapy
HK1115749A (en) Novel compounds and methods for synthesis and therapy
AU2003204079B2 (en) Novel compounds and methods for synthesis and therapy
HK1088594B (en) Novel compounds and methods for synthesis and therapy

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1046359

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20020508

Assignee: Dongyangguang Industry Development Co., Ltd., Shenzhen

Assignor: HOFFMANN LA ROCHE

Contract record no.: 2013990000525

Denomination of invention: Method for preparing neuraminidase inhibitor RO-64-0796

Granted publication date: 20080813

License type: Common License

Record date: 20130827

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CX01 Expiry of patent term

Granted publication date: 20080813

EXPY Termination of patent right or utility model